Saridegib

Quality 0.50 · 0 views · Updated 2 months ago

Experimental drug

title: "Saridegib" type: doc version: 1 created: 2026-02-28 author: "Wikipedia contributors" status: active scope: public tags: ["jervines", "teratogens", "spiro-compounds", "sulfonamides", "experimental-cancer-drugs", "mesyl-compounds"] description: "Experimental drug" topic_path: "general/jervines" source: "https://en.wikipedia.org/wiki/Saridegib" license: "CC BY-SA 4.0" wikipedia_page_id: 0 wikipedia_revision_id: 0

::summary Experimental drug ::

| verifiedrevid = 443867582 | ImageFile = Saridegib.svg | ImageClass = skin-invert-image | ImageSize = | IUPACName = N-[(5βH)-5,6-Dihydro-17,23β-epoxy-16a-homoveratraman-3α-yl]methanesulfonamide | SystematicName = N-[(2S,3R,3′R,3aS,4′aR,6S,6′aR,6′bS,7aR,12′aS,12′bS)-3,6,11′,12′b-Tetramethyl-2′,3′,3a,4,4′,4′a,5,5′,6,6′,6′a,6′b,7,7′,7a,8′,10′,12′,12′a,12′b-icosahydro-1′H,3H-spiro[furo[3,2-b]pyridine-2,9′-naphtho[2,1-a]azulen]-3′-yl]methanesulfonamide | OtherNames = saridegib |Section1={{Chembox Identifiers | IUPHAR_ligand = 8198 | CASNo =1037210-93-7 | CASNo_Ref = | PubChem = 25027363 | ChEMBL = 538867 | ChemSpiderID = 26353073 | UNII_Ref = | UNII = JT96FPU35X | KEGG = D10324 | SMILES = C[C@H]1C[C@@H]2C@HNC1 | StdInChI=1S/C29H48N2O3S/c1-17-12-26-27(30-16-17)19(3)29(34-26)11-9-22-23-7-6-20-13-21(31-35(5,32)33)8-10-28(20,4)25(23)14-24(22)18(2)15-29/h17,19-23,25-27,30-31H,6-16H2,1-5H3/t17-,19+,20+,21+,22-,23-,25-,26+,27-,28-,29-/m0/s1 | StdInChIKey = HZLFFNCLTRVYJG-WWGOJCOQSA-N |Section2={{Chembox Properties | C=29 | H=48 | N=2 | O=3 | S=1 | Appearance = | Density = | MeltingPt = | BoilingPt = | Solubility = }} |Section4={{Chembox Hazards | MainHazards = | FlashPt = | AutoignitionPt = |Section3={{Chembox Pharmacology | Legal_status = Investigational | AdminRoutes = Oral

Saridegib, also known as IPI-926, is an experimental drug candidate undergoing clinical trials for the treatment of various types of cancer, including hard-to-treat hematologic malignancies such as myelofibrosis and ligand-dependent tumors such as chondrosarcoma. IPI-926 exhibits its pharmacological effect by inhibition of the G protein-coupled receptor smoothened, a component of the hedgehog signaling pathway. Chemically, it is a semi-synthetic derivative of the alkaloid cyclopamine. The process begins with cyclopamine extracted from harvested Veratrum californicum which is taken through a series of alterations resulting in an analogue of the natural product cyclopamine, making IPI-926 the only compound in development/testing that is not fully synthetic.

Saridegib is a member of a class of anti-cancer compounds known as hedgehog pathway inhibitors.

References

References

  1. "Pipeline: IPI-926". Infinity Pharmaceuticals.
  2. (2009). "Discovery of a potent and orally active hedgehog pathway antagonist (IPI-926)". Journal of Medicinal Chemistry.

::callout[type=info title="Wikipedia Source"] This article was imported from Wikipedia and is available under the Creative Commons Attribution-ShareAlike 4.0 License. Content has been adapted to SurfDoc format. Original contributors can be found on the article history page. ::

jervinesteratogensspiro-compoundssulfonamidesexperimental-cancer-drugsmesyl-compounds